Company Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
12.43 ^USD	+0.97%		+9.90%	-17.95%

08/05	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	MT
07/05	Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Number of employees: 124

Managers	Title	Age	Since
Kimberly Blackwell CEO	Chief Executive Officer	55	01/20/01
Cam Gallagher FOU	Founder	54	23/14/23
Mark Lackner CTO	Chief Tech/Sci/R&D Officer	56	17/22/17
Diana Hausman CTO	Chief Tech/Sci/R&D Officer	61	08/23/08
Kyle Rasbach IRC	Investor Relations Contact	-	19/01
Kimberly Freeman PRN	Corporate Officer/Principal	-	01/23/01
Alexandra Roy		-	-
Andrea Paul LAW	General Counsel	43	01/22/01
Meena Rao LAW	General Counsel	-	-
Dimitris Voliotis PRN	Corporate Officer/Principal	61	01/20/01

Members of the board	Title	Age	Since
Cam Gallagher FOU	Founder	54	23/14/23
Diana Hausman CTO	Chief Tech/Sci/R&D Officer	61	08/23/08
Karan Takhar BRD	Director/Board Member	32	01/17/01
Jan Skvarka BRD	Director/Board Member	57	12/22/12
Enoch K. Kariuki BRD	Director/Board Member	42	09/21/09
David Johnson CHM	Chairman	59	09/20/09
Kimberly Blackwell CEO	Chief Executive Officer	55	01/20/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,013,233	67,981,965 ( 95.73 %)	0	95.73 %

Name	Equities	%	Valuation
Matrix Capital Management Co. LP 19.67 %	13,959,973	19.67 %	220 M $
Eventide Asset Management LLC 16.29 %	11,559,975	16.29 %	182 M $
Fidelity Management & Research Co. LLC 14.57 %	10,336,971	14.57 %	163 M $
Vanguard Fiduciary Trust Co. 7.540 %	5,350,458	7.540 %	84 M $
BlackRock Advisors LLC 6.265 %	4,445,845	6.265 %	70 M $
STATE STREET CORPORATION 6.225 %	4,417,056	6.225 %	70 M $
Citadel Securities GP LLC 5.189 %	3,681,782	5.189 %	58 M $
T. Rowe Price International Ltd. 4.093 %	2,904,065	4.093 %	46 M $
Capital Research & Management Co. (International Investors) 3.974 %	2,819,664	3.974 %	44 M $
T. Rowe Price Investment Management, Inc. 3.300 %	2,341,783	3.300 %	37 M $

Zentalis Pharmaceuticals, Inc.

1359 Broadway Suite 801

10018, New York

http://www.zentalis.com

address Zentalis Pharmaceuticals, Inc.(ZNTL)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.43 USD

Average target price

33.8 USD

Spread / Average Target

+171.92%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ZENTALIS PHARMACEUTICALS, INC.	-17.95%	874M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	106B
ARGENX SE	+7.02%	23.47B
BIONTECH SE	-14.60%	21.9B
GENMAB A/S	-7.05%	18.77B
WUXI APPTEC CO., LTD.	-38.55%	17.85B
BEIGENE, LTD.	-8.83%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	14.41B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.86B
VIKING THERAPEUTICS, INC.	+329.39%	8.78B

Bio Therapeutic Drugs